How I treat plasma cell leukemia
- 20 September 2012
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 120 (12), 2376-2389
- https://doi.org/10.1182/blood-2012-05-408682
Abstract
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell proliferative disorder with a very poor prognosis and with distinct biologic, clinical, and laboratory features. Compared with multiple myeloma, pPCL presents more often with extramedullary involvement, anemia, thrombocytopenia, hypercalcemia, elevated serum β2-microglobulin and lactate dehydrogenase levels, as well as impaired renal function. Many of the genetic aberrations observed in newly diagnosed pPCL are typically found in advanced multiple myeloma. These cytogenetic abnormalities and mutations lead to increased proliferation, enhanced inhibition of apoptosis, escape from immune surveillance, and independence from the BM microenvironment, with changes in expression of adhesion molecules or chemokine receptors. The outcome of pPCL has improved with the introduction of autologous stem cell transplantation and combination approaches with novel agents, including bortezomib and immunomodulatory drugs, such as lenalidomide. In this review, we provide an overview of currently available therapeutic options with recommendations of how these treatment modalities can best be used to improve outcome for plasma cell leukemia patients.Keywords
This publication has 93 references indexed in Scilit:
- Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsLeukemia, 2012
- IMWG consensus on maintenance therapy in multiple myelomaBlood, 2012
- Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant ResearchLeukemia, 2011
- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBlood, 2011
- Primary plasma cell leukemia and autologous stem cell transplantationHaematologica, 2010
- Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literatureIndian Journal of Medical and Paediatric Oncology, 2010
- Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell LeukaemiaJournal of Oncology, 2009
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3British Journal of Haematology, 2009
- Prognostic Significance of Copy-Number Alterations in Multiple MyelomaJournal of Clinical Oncology, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008